Inventiva Secures Patent in Japan for Lanifibranor

Inventiva has announced that the Japan Patent Office has approved its patent application for the use of lanifibranor in treating cirrhosis. This patent will be valid until November 8, 2039. The patent expands Inventiva’s intellectual property, complementing its existing protection in the United States.

Pierre Broqua, Ph.D., Chief Scientific Officer, commented on the significance of this patent, emphasizing its potential to address medical needs in cirrhosis, including that due to MASH/NASH. The approval highlights lanifibranor's position as a promising treatment candidate for fibrotic diseases.

With about 2.7% of Japan’s population affected by MASH/NASH, and no approved treatment, Japan could be a key market for lanifibranor. Inventiva previously signed an exclusive licensing agreement with Hepalys Pharma for development and commercialization in Japan and South Korea.